Electra Therapeutics Inc. rose 18.3% on Wednesday, November 11, 2026, on 385,200 shares. No headline about ETRA came out that day or the day before in the news feeds we follow, so the move may come from news we don't track, the sector or trading alone.
Electra Therapeutics Inc. (ETRA:NASDAQ) closed at $8.84 on November 13, 2026, down 2.96% on the day. The stock trades 43.0% below its 52-week high of $15.50 and 28.7% above its 52-week low of $6.87. Over the past year, it lost 33.3%. Electra Therapeutics Inc. is part of the Health Care sector.
In 40 trading sessions since September 21, 2026, ETRA closed higher on 14 days (35%). Its best day was November 11, 2026 (+18.27%) and its worst was November 2, 2026 (-9.75%). The stock moved 10% or more in a single session 2 times.
Electra Therapeutics is a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer. The company's novel approach targets signal regulatory proteins (SIRP), a family of cell surface receptors whose expression is restricted to specific immune cell populations and increases upon activation, to enable selective depletion of disease-driving cells while preserving normal immune function. The company's lead product candidate, ipsoprubart (ELA026), is a novel pan-SIRP monoclonal antibody currently in a global registrational program for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory syndrome for which there are no broadly approved therapies and survival has remained consistently poor over the past two decades. Ipsoprubart is also being evaluated in a Phase 1 clinical trial in patients with relapsed/refractory T-cell and natural-killer cell malignancies.
Find more stocks like ETRA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.